Read the docs
TI-2026-05063 Aliases CVE-2026-5781GHSA-9wqr-9q37-v626

Multiple vulnerabilities in MphRx's Minerva

Priority LOW 36CWE-285Published · Updated

Key facts

Attack vector
Network
Privileges required
Low
User interaction
None
Attack complexity
Low
Attack requirements
None
Impact type
Security bypass
Confidentiality · integrity · availability
High · None · None
Fix status
No fix listed

Attack profile from CVSS 4.0 · CNA. Fix status from CNA. Impact type from CWE-285.

Summary

An authorization vulnerability in MphRx's Minerva V3.6.0, specifically in the '/minerva/moUser/update' endpoint, could allow an authenticated user with user modification privileges to escalate their privileges by sending an HTTP request with a manipulated 'identifier' field. Successful exploitation of this vulnerability could allow an authenticated user to obtain administrator privileges. It is not possible to escalate privileges through the graphical user interface.

Why it matters now

Exploitation None reported CISA SSVC · not in CISA KEV
EPSS 0.00232 14th percentileScored 2026-11-07
Fix No fix listed No fixed version in the sources yet

SSVC decision points

CISA ADP · SSVC 2.0.3

Exploitation
None
Automatable
No
Technical impact
Partial

The decision (Track, Attend, Act) also depends on your mission and well-being impact; see CISA's SSVC guide.

Affected products

VendorProductAffected versionsFixed inStatusSource
MphRxMinerva3.6.0—No fix listedCNA
  • Minerva VendorMphRx Affected 3.6.0 Fixed in — No fix listed CNA

CPE configurations NVD · 1

CPEVersionsRoleVendor
cpe:2.3:a:agilonhealth:minerva:3.6.0:*:*:*:*:*:*:*3.6.0VulnerableMphRx
  • cpe:2.3:a:agilonhealth:minerva:3.6.0:*:*:*:*:*:*:* Versions 3.6.0 Vulnerable ·MphRx

Remediation

No fixed version listed by the sources yet.

Timeline

  1. 2026-10-02 Threatist record created from CVE-2026-5781
  2. 2026-10-03 Alias added: GHSA-9wqr-9q37-v626

References

  • TI-2026-05061 Multiple vulnerabilities in MphRx's Minerva CVSS 4.0CRITICAL 9.4
  • TI-2026-05062 Multiple vulnerabilities in MphRx's Minerva CVSS 4.0HIGH 8.5

Sources